chronic hepatitis c infection
Showing 1 - 25 of 53
Against HCV Based on Direct-acting Antivirals in Real-life
Completed
- Chronic Hepatitis C Infection
- Telaprevir
- +10 more
-
Seville, Andalusia, SpainValme University Hospital
Jun 22, 2022
Chronic Hepatitis C Infection Trial in Worldwide (Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin)
Completed
- Chronic Hepatitis C Infection
-
San Francisco, California
- +20 more
Sep 7, 2021
Chronic Hepatitis C Infection Trial in Richmond (HCVax)
Recruiting
- Chronic Hepatitis C Infection
- HCVax
-
Richmond, VirginiaVirginia Commonwealth University, Medical Center
Sep 28, 2021
Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation Trial in Hong Kong (Ledipasvir/Sofosbuvir, Sofosbuvir
Completed
- Chronic Hepatitis C Infection
- +2 more
- Ledipasvir/Sofosbuvir
- +4 more
-
Hong Kong, Hong Kong, ChinaHumanity and Health GI and Liver Centre
Aug 27, 2021
Chronic Hepatitis C Infection Trial in Beijing, Hong Kong (PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF +
Recruiting
- Chronic Hepatitis C Infection
- PR4 + LDV/SOF + ASV 4 wk
- +7 more
-
Beijing, Beijing, China
- +1 more
Aug 27, 2021
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Recruiting
- Chronic Hepatitis C Infection
-
Beijing, Beijing, China
- +2 more
Aug 27, 2021
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for ABT-450/r/ABT-267)
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267, ABT-333
- +4 more
- (no location specified)
Jul 29, 2021
Chronic Hepatitis C Infection, Compensated Cirrhosis Trial (Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir)
Completed
- Chronic Hepatitis C Infection
- Compensated Cirrhosis
- (no location specified)
Jul 8, 2021
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for Ribavirin)
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267, ABT-333
- +2 more
- (no location specified)
Jul 8, 2021
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for ABT-450/r/ABT-267)
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267, ABT-333
- +4 more
- (no location specified)
Jul 8, 2021
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin, Placebo for ribavirin)
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267, ABT-333
- +2 more
- (no location specified)
Jul 8, 2021
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin)
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267, ABT-333
- Ribavirin
- (no location specified)
Jul 8, 2021
Chronic Hepatitis C Infection, Compensated Cirrhosis Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV))
Completed
- Chronic Hepatitis C Infection
- Compensated Cirrhosis
- ABT-450/r/ABT-267, ABT-333
- Ribavirin (RBV)
- (no location specified)
Jul 8, 2021
Chronic Hepatitis C Infection Trial in United States (Fuzheng Huayu, Placebo)
Completed
- Chronic Hepatitis C Infection
- Fuzheng Huayu
- Placebo
-
Coronado, California
- +7 more
Apr 28, 2021
Chronic Hepatitis C Infection Trial in Taiwan (JNJ-47910382 30 mg, JNJ-47910382 90 mg, JNJ-47910382 200 mg)
Terminated
- Chronic Hepatitis C Infection
- JNJ-47910382 30 mg
- +3 more
-
Kaohsiung, Taiwan
- +4 more
Mar 25, 2019
Chronic Hepatitis C Infection Trial in United States (ABT-267, ABT-450, ABT-333)
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, Placebo)
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267
- Placebo
- (no location specified)
May 2, 2018
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin, Pegylated Interferon a-2a (PegINF))
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267, ABT-333
- +3 more
- (no location specified)
May 2, 2018
Chronic Hepatitis C Infection Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin, Telaprevir)
Completed
- Chronic Hepatitis C Infection
- ABT-450/r/ABT-267, ABT-333
- +3 more
- (no location specified)
May 2, 2018
Chronic Hepatitis C Infection Trial (ABT-450/ritonavir, ABT-267)
Completed
- Chronic Hepatitis C Infection
- ABT-450/ritonavir, ABT-267
- (no location specified)
Apr 30, 2018
Chronic Hepatitis C Infection, Chronic Hepatitis C Trial (ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV))
Completed
- Chronic Hepatitis C Infection
- Chronic Hepatitis C
- ABT-450/r/ABT-267
- +2 more
- (no location specified)
Apr 30, 2018
Chronic Hepatitis C Infection Trial in Beijing, Hong Kong (SOF+RBV, SOF+DCV, LDV/SOF)
Completed
- Chronic Hepatitis C Infection
- SOF+RBV
- +2 more
-
Beijing, Beijing, China
- +1 more
Mar 16, 2018
Chronic Hepatitis C Infection Trial in Beijing, Hong Kong (sofosbuvir and daclatasvir, ledipasvir/sofosbuvir)
Completed
- Chronic Hepatitis C Infection
- sofosbuvir and daclatasvir
- ledipasvir/sofosbuvir
-
Beijing, Beijing, China
- +1 more
Mar 16, 2018
Chronic Hepatitis C Infection Trial in Beijing, Hong Kong (Sofosbuvir, Daclatasvir)
Completed
- Chronic Hepatitis C Infection
-
Beijing, Beijing, China
- +1 more
Mar 16, 2018
Chronic Hepatitis C Infection Trial (ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin)
Completed
- Chronic Hepatitis C Infection
- ombitasvir/paritaprevir/ritonavir and dasabuvir
- +2 more
- (no location specified)
Nov 22, 2017